| | | | | | | | | | | | | | | | |
| |
![Collapse](/DXR.axd?r=1_87-p7f1t) | Issue Date FY: 2024 ( Subtotal = $116,300,757 ) (Continued on the next page) |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE033330 | Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral Premalignancy | 002 | 2 | NIH | 7/18/2024 | $675,425 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA286318 | Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H1 | 000 | 1 | NIH | 2/14/2024 | $227,205 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA282027 | Bhlhe40 Regulation of T Cell Function During Cancer Immunotherapy | 000 | 1 | NIH | 5/30/2024 | $606,635 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA289456 | Targeting the gut microbiome to inhibit melanoma lymph node metastases | 000 | 1 | NIH | 4/26/2024 | $530,612 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DK132019 | Angiotensin Signaling Underlies Myeloid and Sensory Disruption in Diabetes | 000 | 1 | NIH | 5/2/2024 | $480,845 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA289563 | Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor | 000 | 1 | NIH | 3/8/2024 | $81,000 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA288448 | Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies | 000 | 1 | NIH | 3/4/2024 | $672,300 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288515 | Strategies for Personalizing Oxygen and support Therapies for dyspnea in Oncology | 000 | 1 | NIH | 4/12/2024 | $655,203 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA274085 | Impact of tamoxifen treatment on neutrophils in breast cancer patients | 000 | 1 | NIH | 3/7/2024 | $191,704 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 000 | 1 | NIH | 2/28/2024 | $214,399 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269140 | Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | 001 | 2 | NIH | 4/17/2024 | $24,007 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269140 | Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | 000 | 2 | NIH | 12/12/2023 | $432,117 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 002 | 2 | NIH | 5/13/2024 | $44,519 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 001 | 2 | NIH | 2/2/2024 | $0 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 000 | 2 | NIH | 1/17/2024 | $500,835 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21HD110642 | Spatio-temporal regulation of ERK signaling by phosphatases in the female germline | 001 | 2 | NIH | 5/2/2024 | $20,250 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21HD110642 | Spatio-temporal regulation of ERK signaling by phosphatases in the female germline | 000 | 2 | NIH | 1/25/2024 | $182,250 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R34AT012360 | Randomized controlled trial to test feasibility of a culturally adapted meditation-based support intervention for Black patients dealing with advanced cancer | 000 | 2 | NIH | 11/17/2023 | $218,700 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 004 | 2 | NIH | 4/30/2024 | $3,190 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 003 | 2 | NIH | 4/17/2024 | $9,465 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 002 | 2 | NIH | 2/19/2024 | $0 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 001 | 2 | NIH | 11/16/2023 | $57,406 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 000 | 2 | NIH | 11/15/2023 | $170,405 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA260661 | Metabolic basis of ARID1A-mutated ovarian cancer | 001 | 3 | NIH | 4/17/2024 | $24,484 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM155107 | Dissecting the role of DNA methylation in controlling retrotransposons and governing adult stem cell fates | 000 | 1 | NIH | 7/23/2024 | $408,750 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279467 | Novel PET Imaging to Guide Therapy in Hepatocellular Carcinoma | 000 | 1 | NIH | 7/22/2024 | $678,515 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL163857 | Premature aging disorders, metabolites, and atherosclerosis | 002 | 2 | NIH | 6/8/2024 | $57,528 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279749 | Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events | 000 | 1 | NIH | 1/19/2024 | $657,119 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01HL163857 | Premature aging disorders, metabolites, and atherosclerosis | 001 | 2 | NIH | 11/16/2023 | $647,209 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275990 | Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer | 001 | 2 | NIH | 4/16/2024 | $29,404 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275990 | Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer | 000 | 2 | NIH | 12/15/2023 | $529,259 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA279867 | Calcium metabolism and lung cancer preneoplasia | 000 | 1 | NIH | 1/1/2024 | $81,000 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279452 | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor | 000 | 1 | NIH | 12/19/2023 | $672,297 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278971 | Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling | 000 | 1 | NIH | 12/29/2023 | $623,452 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA286992 | Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types | 000 | 1 | NIH | 12/20/2023 | $189,338 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278967 | CRACD-controlled cell plasticity and small cell lung cancer | 000 | 1 | NIH | 12/27/2023 | $599,733 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277152 | Preclinical studies of non-nucleoside DNMT3A/3B inhibitors | 000 | 1 | NIH | 12/26/2023 | $227,205 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA259749 | A combination strategy to target pathophysiology of chronic lymphocytic leukemia | 001 | 2 | NIH | 4/17/2024 | $11,361 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA259749 | A combination strategy to target pathophysiology of chronic lymphocytic leukemia | 000 | 2 | NIH | 1/15/2024 | $204,485 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HD113569 | Reproductive tract organ development and differentiation | 000 | 1 | NIH | 7/19/2024 | $510,741 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA292908 | Lymphedema Prevention Through Immediate Lymphatic Reconstruction | 000 | 1 | NIH | 7/19/2024 | $516,114 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MD017999 | Health equity in fertility specialty care among cancer survivors | 002 | 2 | NIH | 5/31/2024 | $68,346 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MD017999 | Health equity in fertility specialty care among cancer survivors | 001 | 2 | NIH | 12/9/2023 | $615,106 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 001 | 1 | NIH | 12/22/2023 | $0 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 000 | 1 | NIH | 12/20/2023 | $923,199 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA273661 | A novel uterine leiomyosarcoma mouse model for therapeutic development | 000 | 1 | NIH | 1/11/2024 | $227,205 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA236864 | DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS | 001 | 5 | NIH | 4/15/2024 | $18,529 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA236864 | DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS | 000 | 5 | NIH | 11/20/2023 | $333,518 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS101880 | Molecular Determinants of Synaptic Plasticity in Chronic Pain | 001 | 7 | NIH | 5/3/2024 | $35,144 |
|